alexa
Indianmoney.com Missed Call Number

What is your Credit Score? Get FREE Credit Score in 1 Minute!

Get Start Now!
 
Home News Eris Lifesciences

Read more interesting news from around the globe with Indianmoney App

Google Play
 
News Image

Eris Lifesciences IPO: #4 Risks

Thursday, June 15, 2017, 3:58 PM

The brokerage believes that any changes on the policy front could hurt the company. Moreover, high dependence on top 10 products could be another risk. This, coupled with threat of product conversion from brands to generics and the uncertainty with pharma pricing could hurt the company.
News Image

Eris Lifesciences IPO: #3 Financials

Thursday, June 15, 2017, 3:52 PM

The 10-year old drugmaker generates over two-thirds of its revenues from anti-diabetic and cardiovascular segments with margins as high as 75-80 percent. In fact, top 10 brands of Eris Lifesciences contributes about 74 percent of the company’s revenues. Meanwhile, its EBITDA for FY17 stood at Rs 268.6 crore, while margin came in at 37.1 percent.
News Image

Eris Lifesciences IPO: #2 Company Profile

Thursday, June 15, 2017, 3:44 PM

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the Indian pharmaceutical market such as cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. It has a team of over 2,287 employees across India as on September 30, 2016. Around 12-14% of Eris Lifesciences portfolio is under NLEM where the prices are controlled by the government.

What is your Credit Score? Get FREE Credit Score in 1 Minute!

Get Start Now!
CIBIL Meter
Get It now!